Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

321 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity.
Gan HK, Millward M, Hua Y, Qi C, Sai Y, Su W, Wang J, Zhang L, Frigault MM, Morgan S, Yang L, Lickliter JD. Gan HK, et al. Among authors: sai y. Clin Cancer Res. 2019 Aug 15;25(16):4924-4932. doi: 10.1158/1078-0432.CCR-18-1189. Epub 2019 Apr 5. Clin Cancer Res. 2019. PMID: 30952639 Clinical Trial.
Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer.
Jia H, Dai G, Weng J, Zhang Z, Wang Q, Zhou F, Jiao L, Cui Y, Ren Y, Fan S, Zhou J, Qing W, Gu Y, Wang J, Sai Y, Su W. Jia H, et al. Among authors: sai y. J Med Chem. 2014 Sep 25;57(18):7577-89. doi: 10.1021/jm500510f. Epub 2014 Sep 15. J Med Chem. 2014. PMID: 25148209
Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.
Sun Q, Zhou J, Zhang Z, Guo M, Liang J, Zhou F, Long J, Zhang W, Yin F, Cai H, Yang H, Zhang W, Gu Y, Ni L, Sai Y, Cui Y, Zhang M, Hong M, Sun J, Yang Z, Qing W, Su W, Ren Y. Sun Q, et al. Among authors: sai y. Cancer Biol Ther. 2014;15(12):1635-45. doi: 10.4161/15384047.2014.964087. Cancer Biol Ther. 2014. PMID: 25482937 Free PMC article.
Immunological characterization of HM5023507, an orally active PI3Kδ/γ inhibitor.
Cai Y, Yu J, Ren P, He J, Wu Z, Xiao K, Jia H, Wang J, Sai Y, Dai G, Li X, Su W, Ngo K, Castro G, Acton PD, Fung-Leung WP, Edwards JP, Venable J, Rao TS. Cai Y, et al. Among authors: sai y. Pharmacol Res Perspect. 2020 Jan 13;8(1):e00559. doi: 10.1002/prp2.559. eCollection 2020 Feb. Pharmacol Res Perspect. 2020. PMID: 31956418 Free PMC article.
321 results